Scholarlink

Background <p>Visit-to-visit systolic blood pressure variability (BPV) has been linked to cognitive decline, but inter-individual susceptibility may depend on modifiable factors such as vitamin D status. We investigated whether baseline serum 25-hydroxyvitamin D [25(OH)D] modifies the association between systolic BPV and 12-month cognition among older adults with hypertension.</p> Methods <p>In this single-center prospective cohort, participants were recruited from May 2023 to June 2024 and followed for 12 months, adults aged ≥ 65 years with hypertension underwent baseline 25(OH)D measurement and Montreal Cognitive Assessment (MoCA) at baseline and Month 12. BPV was calculated from clinic SBP values during Months 0–10 (≥ 6 visits required). Average real variability of SBP (ARV-SBP) was the primary BPV metric; standard deviation (SD-SBP), coefficient of variation (CV-SBP), variability independent of mean (VIM-SBP), and range-SBP were examined in sensitivity analyses. Average real variability of SBP (ARV-SBP) was the primary BPV metric. The primary analysis used ANCOVA-style multivariable linear regression for Month 12 MoCA including ARV-SBP (per 1 SD), 25(OH)D (per 10 ng/mL, centered), and their interaction, adjusting for baseline MoCA and prespecified covariates. A screening-based, algorithm-defined MCI status at Month 12 was analyzed using modified Poisson regression with robust standard errors.</p> Results <p>Among 176 participants (mean age 73.1 years), 73 (41.5%) had low vitamin D status [25(OH)D &lt; 20 ng/mL] and 48 (27.3%) met algorithm-defined MCI status at Month 12. Higher ARV-SBP was associated with lower Month 12 MoCA (β=−0.22, 95% CI − 0.37 to − 0.07 β), and 25(OH)D significantly modified this association (interaction β = 0.18, 95% CI 0.05 to 0.32; <i>p</i> = 0.01 β), indicating attenuation of BPV-related cognitive disadvantage at higher vitamin D levels. The interaction remained directionally consistent across SD-SBP, CV-SBP, VIM-SBP, and range-SBP sensitivity models (all nominal <i>p</i> ≤ 0.04 ; FDR q ≤ 0.04 ). In joint-exposure analysis, low vitamin D status plus high BPV was associated with a higher probability of meeting algorithm-defined MCI status versus 25(OH)D ≥ 20 ng/mL with low BPV (adjusted RR = 4.14, 95% CI 1.93 to 8.90), while additive interaction was suggestive but imprecise (RERI = 1.94, 95% CI − 0.10 to 6.03).</p> Conclusions <p>Baseline 25(OH)D was associated with heterogeneity in the observed association between clinic visit-to-visit systolic BPV and 12-month cognition in adults aged ≥ 65 years with hypertension. These findings support attention to BP stability and low vitamin D status as a potential marker of cognitive vulnerability in older hypertensive outpatients, while causal inference and supplementation effects require confirmation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Interactive effects of vitamin D status and visit-to-visit systolic blood pressure variability on 12-month cognition and mild cognitive impairment in older adults with hypertension

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月22日

查看全文
  • Linya Zhao,
  • Pengran Wang,
  • Hongmei Zhao,
  • Nuan Xiao,
  • Lili Tan

摘要

Background

Visit-to-visit systolic blood pressure variability (BPV) has been linked to cognitive decline, but inter-individual susceptibility may depend on modifiable factors such as vitamin D status. We investigated whether baseline serum 25-hydroxyvitamin D [25(OH)D] modifies the association between systolic BPV and 12-month cognition among older adults with hypertension.

Methods

In this single-center prospective cohort, participants were recruited from May 2023 to June 2024 and followed for 12 months, adults aged ≥ 65 years with hypertension underwent baseline 25(OH)D measurement and Montreal Cognitive Assessment (MoCA) at baseline and Month 12. BPV was calculated from clinic SBP values during Months 0–10 (≥ 6 visits required). Average real variability of SBP (ARV-SBP) was the primary BPV metric; standard deviation (SD-SBP), coefficient of variation (CV-SBP), variability independent of mean (VIM-SBP), and range-SBP were examined in sensitivity analyses. Average real variability of SBP (ARV-SBP) was the primary BPV metric. The primary analysis used ANCOVA-style multivariable linear regression for Month 12 MoCA including ARV-SBP (per 1 SD), 25(OH)D (per 10 ng/mL, centered), and their interaction, adjusting for baseline MoCA and prespecified covariates. A screening-based, algorithm-defined MCI status at Month 12 was analyzed using modified Poisson regression with robust standard errors.

Results

Among 176 participants (mean age 73.1 years), 73 (41.5%) had low vitamin D status [25(OH)D < 20 ng/mL] and 48 (27.3%) met algorithm-defined MCI status at Month 12. Higher ARV-SBP was associated with lower Month 12 MoCA (β=−0.22, 95% CI − 0.37 to − 0.07 β), and 25(OH)D significantly modified this association (interaction β = 0.18, 95% CI 0.05 to 0.32; p = 0.01 β), indicating attenuation of BPV-related cognitive disadvantage at higher vitamin D levels. The interaction remained directionally consistent across SD-SBP, CV-SBP, VIM-SBP, and range-SBP sensitivity models (all nominal p ≤ 0.04 ; FDR q ≤ 0.04 ). In joint-exposure analysis, low vitamin D status plus high BPV was associated with a higher probability of meeting algorithm-defined MCI status versus 25(OH)D ≥ 20 ng/mL with low BPV (adjusted RR = 4.14, 95% CI 1.93 to 8.90), while additive interaction was suggestive but imprecise (RERI = 1.94, 95% CI − 0.10 to 6.03).

Conclusions

Baseline 25(OH)D was associated with heterogeneity in the observed association between clinic visit-to-visit systolic BPV and 12-month cognition in adults aged ≥ 65 years with hypertension. These findings support attention to BP stability and low vitamin D status as a potential marker of cognitive vulnerability in older hypertensive outpatients, while causal inference and supplementation effects require confirmation.